Research graph
References from New treatment approaches for superficial and invasive bladder cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892)
10.1002/(sici)1097-0142(19970101)79:1<110::aid-cncr16>3.0.co;2-7 · 1997 · External reference
Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies
10.1016/s0022-5347(01)66765-x · 1995 · External reference
Oral methotrexate for superficial transitional cell carcinoma of the bladder
10.1016/s0022-5347(17)36281-x · 1995 · External reference
Prophylactic oral UFT therapy for superficial bladder cancer
10.1002/1097-0142(19930301)71:5<1842::aid-cncr2820710520>3.0.co;2-2 · 1993 · External reference
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP study group
10.1159/000475138 · 1995 · External reference
Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells
10.1006/jsre.1995.1222 · 1995 · External reference
Initial report on intravesical administration of n-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder
10.1016/s0090-4295(96)00621-8 · 1997 · External reference
Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody
10.1007/bf02789217 · 1994 · External reference
Radioimmunoimaging diagnosis of human bladder carcinoma
1994 · External reference
Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder
10.1007/bf00297203 · 1994 · External reference
Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas
10.1002/ijc.2910540604 · 1993 · External reference
Oral bropirimine immunotherapy of carcinoma in situ of the bladder
10.1016/s0090-4295(96)90059-x · 1996 · External reference
How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
10.1111/j.1464-410x.1991.tb15393.x · 1991 · External reference
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b
10.1200/jco.1994.12.1.7 · 1994 · External reference
A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group
10.1111/j.1464-410x.1995.tb00759.x · 1995 · External reference
Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors. Portuguese Genito-Urinary Group
10.1159/000475069 · 1995 · External reference
Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
10.1016/s0090-4295(96)00375-5 · 1996 · External reference
Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin
10.1016/s0094-0143(21)00425-0 · 1992 · External reference
Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2
10.1159/000475070 · 1995 · External reference
Immunologic reduction of bladder cancer recurrence rate
10.1016/s0022-5347(17)59919-x · 1974 · External reference
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin
10.1016/s0022-5347(17)42610-3 · 1988 · External reference
Recurrent superficial transitional cell carcinoma of the bladder
10.1016/s0022-5347(17)39427-2 · 1990 · External reference
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer
10.1016/s0022-5347(01)67228-8 · 1995 · External reference
Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors? A phase II study
10.1111/j.1442-2042.1995.tb00433.x · 1995 · External reference
Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma
10.1111/j.1464-410x.1976.tb02742.x · 1996 · External reference
Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence
10.1016/s0022-5347(17)52205-3 · 1983 · External reference
The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial
10.1111/j.1464-410x.1994.tb07547.x · 1994 · External reference
10.1016/s0022-5347(17)36198-0
10.1016/s0022-5347(17)36198-0 · 1993 · External reference
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer
10.1016/s0022-5347(01)66226-8 · 1996 · External reference
Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer
10.1016/s0022-5347(01)66225-6 · 1996 · External reference
A feasibility study for the non-invasive treatment of superficial bladder tumours with focused ultrasound
10.1046/j.1464-410x.1996.02189.x · 1996 · External reference
Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer
10.1046/j.1464-410x.1996.09717.x · 1996 · External reference
Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells
10.1084/jem.177.4.1127 · 1993 · External reference
Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
1994 · External reference
Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
10.4049/jimmunol.159.1.351 · 1997 · External reference
Adenovirus-mediated suicide gene therapy for experimental bladder cancer
10.1016/s0090-4295(96)00560-2 · 1997 · External reference
Intravesical gene therapy
1994 · External reference
Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo
1995 · External reference
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy
10.1016/s0022-5347(17)32741-6 · 1994 · External reference
Megadose vitamins in bladder cancer
10.1016/s0022-5347(17)34863-2 · 1994 · External reference
10.1159/000475139
10.1159/000475139 · 1995 · External reference
13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group
10.1002/jcb.240501328 · 1992 · External reference
Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland
10.1159/000475068 · 1995 · External reference
Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point
10.1093/jnci/86.2.138 · 1994 · External reference
10.1002/(sici)1097-4644(1996)25+<197::aid-jcb28>3.0.co;2-k
10.1002/(sici)1097-4644(1996)25+<197::aid-jcb28>3.0.co;2-k · External reference
Toxicity evaluation of difluoromethylornithine
1996 · External reference
